These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 29702148)

  • 1. Immunomodulatory effects of CD38-targeting antibodies.
    van de Donk NWCJ
    Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reprint of "Immunomodulatory effects of CD38-targeting antibodies".
    van de Donk NWCJ
    Immunol Lett; 2019 Jan; 205():71-77. PubMed ID: 30826127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
    van de Donk NWCJ; Usmani SZ
    Front Immunol; 2018; 9():2134. PubMed ID: 30294326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.
    van de Donk NW; Janmaat ML; Mutis T; Lammerts van Bueren JJ; Ahmadi T; Sasser AK; Lokhorst HM; Parren PW
    Immunol Rev; 2016 Mar; 270(1):95-112. PubMed ID: 26864107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daratumumab prevents programmed death ligand-1 expression on antigen-presenting cells in de novo multiple myeloma.
    Stocker N; Gaugler B; Ricard L; de Vassoigne F; Marjanovic Z; Mohty M; Malard F
    Cancer Med; 2020 Mar; 9(6):2077-2084. PubMed ID: 31991058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daratumumab: monoclonal antibody therapy to treat multiple myeloma.
    Xia C; Ribeiro M; Scott S; Lonial S
    Drugs Today (Barc); 2016 Oct; 52(10):551-560. PubMed ID: 27910963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials.
    Ye W; Wu X; Liu X; Zheng X; Deng J; Gong Y
    BMC Cancer; 2021 Sep; 21(1):994. PubMed ID: 34488679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
    Djebbari F; Poynton M; Sangha G; Anderson L; Maddams R; Eyre TA; Vallance G; Basu S; Ramasamy K
    Hematology; 2022 Dec; 27(1):204-207. PubMed ID: 35134321
    [No Abstract]   [Full Text] [Related]  

  • 9. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
    Raab MS; Engelhardt M; Blank A; Goldschmidt H; Agis H; Blau IW; Einsele H; Ferstl B; Schub N; Röllig C; Weisel K; Winderlich M; Griese J; Härtle S; Weirather J; Jarutat T; Peschel C; Chatterjee M
    Lancet Haematol; 2020 May; 7(5):e381-e394. PubMed ID: 32171061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD38 antibodies in multiple myeloma: back to the future.
    van de Donk NWCJ; Richardson PG; Malavasi F
    Blood; 2018 Jan; 131(1):13-29. PubMed ID: 29118010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience.
    Frerichs KA; Nagy NA; Lindenbergh PL; Bosman P; Marin Soto J; Broekmans M; Groen RWJ; Themeli M; Nieuwenhuis L; Stege C; Nijhof IS; Mutis T; Zweegman S; Lokhorst HM; van de Donk NWCJ
    Expert Rev Clin Immunol; 2018 Mar; 14(3):197-206. PubMed ID: 29465271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical characterization of a novel investigational monoclonal antibody CM313 with potent CD38-positive cell killing activity.
    Liu W; Yu J; Sun K; Song Q; Li Y; He Y; Wang Y; Xu G; Wang C; Chen B
    Front Immunol; 2024; 15():1410457. PubMed ID: 38765013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [CD38 antibodies in multiple myeloma].
    Moreaux J
    Med Sci (Paris); 2019 Dec; 35(12):1001-1004. PubMed ID: 31903907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy.
    Zamagni E; Tacchetti P; Pantani L; Cavo M
    Expert Rev Hematol; 2018 May; 11(5):423-435. PubMed ID: 29582696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.
    van der Veer MS; de Weers M; van Kessel B; Bakker JM; Wittebol S; Parren PW; Lokhorst HM; Mutis T
    Haematologica; 2011 Feb; 96(2):284-90. PubMed ID: 21109694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.
    Martin TG; Corzo K; Chiron M; Velde HV; Abbadessa G; Campana F; Solanki M; Meng R; Lee H; Wiederschain D; Zhu C; Rak A; Anderson KC
    Cells; 2019 Nov; 8(12):. PubMed ID: 31779273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells.
    Paulus A; Manna A; Akhtar S; Paulus SM; Sharma M; Coignet MV; Jiang L; Roy V; Witzig TE; Ansell SM; Allan J; Furman R; Aulakh S; Manochakian R; Ailawadhi S; Chanan-Khan AA; Sher T
    Br J Haematol; 2018 Oct; 183(2):196-211. PubMed ID: 30080238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting NAD
    Kennedy BE; Sadek M; Elnenaei MO; Reiman A; Gujar SA
    Trends Cancer; 2020 Jan; 6(1):9-12. PubMed ID: 31952784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma.
    Sanchez L; Wang Y; Siegel DS; Wang ML
    J Hematol Oncol; 2016 Jun; 9(1):51. PubMed ID: 27363983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
    Plesner T; van de Donk N; Richardson PG
    Cells; 2020 Feb; 9(2):. PubMed ID: 32041300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.